Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2016

Conditions
Acute Lymphoid Leukemia
Interventions
PROCEDURE

alloHCT

"\[ alloHCT arm \] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg\*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg\* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg\*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."

Trial Locations (2)

Unknown

Inje University Haeundae Paik Hospital, Pusan

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER